1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Spinal Muscular Atrophy Market - Pipeline Assessment, Size, Growth, Trends, and Forecast 2015 - 2023

Pipeline analysis of spinal muscular atrophy (SMA) market report provides with comprehensive analysis of drugs in clinical trials for treatment for spinal muscular atrophy. The report provides insights to SMA prevalence, and current treatment pattern. The report also identifies key market drivers, restraints and opportunities in the global spinal muscular atrophy therapeutics market. Detailed market attractiveness analysis by geography provides future outlook to the spinal muscular atrophy landscape. Market attractiveness analysis considers various factors such as patient population, drug pricing policies, regulatory restrictions, current competition intensity, and current state of healthcare sector for assessing the potential of each geographical market.
In the pipeline analysis of spinal muscular atrophy (SMA) market report, market analysis and forecast has been provided for late stage (phase 3) candidates, while also includes thorough qualitative information for other candidates in early stage (phase 1 and phase 2). ISIS-SMNRx by Isis Pharmaceuticals is presently the only late stage candidate in spinal muscular atrophy pipeline, while three drugs are currently in phase 2 and three others in phase 1. These include Olesoxime (TRO19622), LMI070, RO6885247, CK-2127107, scAAV9.CB.SMN and RG3039. The report also mentions some of the potential preclinical candidates in the spinal muscular atrophy pipeline. The pipeline analysis of spinal muscular atrophy (SMA) market report provides overview of the clinical trials, and its current status for each drug candidate for treatment of spinal muscular atrophy. Details on mergers, acquisitions, licensing agreements, and other collaborative agreements, updated on regulatory policies, and expected study completion are also mentioned in the report. Market estimation and forecast for phase 3 drugs for treatment of spinal muscular atrophy has been provided from the expected year of drug approval, till 2023 (in USD Million) for the United States.
Pipeline analysis of late stage (phase 3) drugs for treatment of spinal muscular atrophy adopts patient based approach, in which actual patient population that can be targeted by the new drug is considered to arrive at probable sales of the drug in the launch year. Forecast model considers various macro- as well as micro-economic factors such as drug efficiency, side effects, prevalence and incidence rate, impact of regulatory policies, impact of competitor drugs and generic competition (if applicable) and pipeline status. The report collates information from various government as well as corporate sources such as Europe and the U.S. clinical trial registries, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), CureSMA, Families of SMA, PubMed, company press releases, annual reports and investor presentations. The analysis also considers inputs from industry experts and key opinion leaders with expertise in rare disease drug discovery, and marketing and sales experts.
Key players with potential candidates in clinical trials for treatment of spinal muscular atrophy have been profiled in the report. These include AveXis, Inc., Cytokinetics, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Isis Pharmaceuticals, Inc. Each of the company profile provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.

Table Of Contents

Spinal Muscular Atrophy Market - Pipeline Assessment, Size, Growth, Trends, and Forecast 2015 - 2023
Chapter 1 Introduction
1.1 Report Description
1.2 Research Methodology
1.3 Market Segmentation
1.4 Assumptions
Chapter 2 Executive Summary
2.1 Pipeline Analysis: Spinal Muscular Atrophy- Market Snapshot
Chapter 3 Pipeline Analysis: Spinal Muscular Atrophy Market Overview
3.1 Market Definition and Overview
3.2 Current Treatment for Spinal Muscular Atrophy
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Restraints
3.3.3 Opportunities
3.3 Market Attractiveness Analysis
Chapter 4 : Pipeline Analysis: Spinal Muscular Atrophy
4.1 Spinal Muscular Atrophy: Pipeline Overview
4.2 Late Stage Candidates (Phase 3)
4.2.1 ISIS-SMN Rx
4.3 Early Stage Candidates (Phase 1 and Phase 2)
4.3.1 Olesoxime (TRO19622)
4.3.2 LMI070
4.3.3 RO6885247
4.3.4 CK-2127107
4.3.5 scAAV9.CB.SMN
4.3.6 RG3039
Chapter 5 Recommendation
Chapter 6 Company Profiles
6.1 AveXis, Inc.
6.2 Cytokinetics, Inc.
6.3 F. Hoffmann-La Roche Ltd.
6.4 Novartis AG
6.5 Isis Pharmaceuticals, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Bioinformatics Market by Sector (Molecular Medicine, Agriculture, Forensic, Animal, Research & Gene Therapy), Product (Sequencing Platforms, Knowledge Management & Data Analysis) & Application (Genomics, Proteomics & Metabolomics) - Global Forecast to 202

Bioinformatics Market by Sector (Molecular Medicine, Agriculture, Forensic, Animal, Research & Gene Therapy), Product (Sequencing Platforms, Knowledge Management & Data Analysis) & Application (Genomics, Proteomics & Metabolomics) - Global Forecast to 202

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global bioinformatics market is projected to reach USD 16.18 billion by 2021 from USD 6.21 billion in 2016, growing at a CAGR of 21.1% during the forecast period. In this report, the bioinformatics ...

Abdominal Aortic Stent Grafts - Medical Devices Pipeline Assessment, 2016

Abdominal Aortic Stent Grafts - Medical Devices Pipeline Assessment, 2016

  • $ 4000
  • Industry report
  • October 2016
  • by Global Data

Abdominal Aortic Stent Grafts - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Abdominal Aortic Stent Grafts - Medical Devices Pipeline Assessment, 2016" ...

Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

  • $ 4000
  • Industry report
  • September 2016
  • by Global Data

Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.